Abstract
Small cell lung cancer (SCLC) is a common pathological type of primary lung cancer originating from the bronchial mucosa or gland. SCLC is characterized by rapid growth, high degree of malignancy, and early metastasis, which poses a great threat to patients’ safety and quality of life. SCLC can be divided into two stages: localized disease and extensive disease. For limited-disease small cell lung cancer (LD-SCLC), radiotherapy and chemotherapy are often used in clinical treatment. In recent years, there are several new advances in the clinical treatment of SCLC, including the improvement of radiotherapy and chemotherapy methods, compatibility of first-line and second-line drugs, as well as immune-targeted therapy. This article discusses the current status of clinical treatment and the research progress of LD-SCLC in the past five years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
